2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms (MPNs).
In recent years, cellular therapy has evolved rapidly in lymphoid malignancies, especially in lymphoma and multiple myeloma, says Mesa.
Notably, at the Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Paul J. Shaughnessy, MD, of Methodist Hospital, expanded on these data and provided insight on future directions of CAR T-cell therapy in hematologic malignancies.
The utility of cellular-based therapy, in both hematologic and non-hematologic malignancies, has sparked great interest across oncology. Encouraging data suggest CAR T-cell therapy may soon find a place in the MPNs space, concludes Mesa.